Apollomics (APLM) AI Stock Analysis

• Market Cap: $7.40M
• Dividend Yield: N/A
• Average Volume (3M): 29.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.36
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 45
• Sector: Healthcare
• Sector Strength: 78
• Industry: Biotechnology
• EPS (TTM): -0.62
• Shares Outstanding: 1,102,665
• 10 Day Avg. Volume: 80,697
• 30 Day Avg. Volume: 29,396
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Apollomics faces considerable financial hurdles with negative profitability and cash flows, exerting significant pressure on its stock score. Technical indicators are generally bearish, and valuation metrics are unattractive due to losses. The absence of new insights from the earnings call adds uncertainty, resulting in a low overall score.

Apollomics Business Overview & Revenue Model

Company Description

Apollomics, Inc., a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain. The company was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2015 and is based in Foster City, California.

How the Company Makes Money

Apollomics makes money primarily through the development and commercialization of its oncology therapies. The company engages in strategic partnerships and licensing agreements with other pharmaceutical companies to co-develop drugs, which can provide upfront payments, milestone payments, and royalties on sales. Additionally, Apollomics may generate revenue from government grants or research funding, as well as from the eventual sale or out-licensing of successful therapies in its pipeline.

Apollomics Financial Statement Overview

Summary

Apollomics demonstrates significant financial challenges with persistent losses, high leverage, and negative cash flows. Despite slight improvements in equity and revenue growth, the company struggles with profitability and cash flow generation.

Income Statement

Apollomics shows a consistent pattern of negative profitability with significant net losses over multiple years. The company reported a negative gross profit margin and declining EBIT and EBITDA margins. While there is revenue growth from 2022 to 2023, the overall financial health in terms of profitability remains weak.

Balance Sheet

The balance sheet indicates a high level of liabilities relative to equity, resulting in a negative debt-to-equity ratio historically. Although the equity improved to positive in 2023, which is a positive sign, the overall leverage remains a concern. The equity ratio is relatively low for the biotechnology industry, suggesting potential financial instability.

Cash Flow

Cash flows are challenging, with negative operating cash flow and free cash flow across the years. There was a slight improvement in 2023's free cash flow growth rate, but the operating cash flow to net income ratio indicates inefficiencies in turning income into cash. Cash flow management remains a crucial area for improvement.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
2.27M	821.00K	323.00K	2.00K	1.84M	0.00
	Gross Profit
2.27M	127.00K	-452.00K	-679.00K	1.23M	-369.00K
	EBIT
-53.01M	-54.83M	-240.21M	-91.75M	-74.08M	-24.75M
	EBITDA
-53.02M	-171.75M	-239.94M	-94.03M	-74.22M	-45.34M
	Net Income Common Stockholders
-57.11M	-172.60M	-240.81M	-94.80M	-74.82M	-45.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
154.51M	37.82M	54.61M	94.48M	154.39M	74.12M
	Total Assets
0.00	55.39M	76.47M	123.44M	169.94M	79.05M
	Total Debt
0.00	4.66M	991.00K	1.04M	1.51M	135.97M
	Net Debt
154.51M	-27.39M	-31.68M	-45.70M	-129.13M	97.48M
	Total Liabilities
0.00	14.15M	524.60M	336.30M	297.87M	139.78M
	Stockholders Equity
-127.93M	41.23M	-448.12M	-212.86M	-127.93M	-60.72M
Cash Flow		Free Cash Flow
-34.82M	-43.22M	-43.19M	-50.86M	-45.83M	-22.80M
	Operating Cash Flow
-34.80M	-43.21M	-42.82M	-43.31M	-35.68M	-21.94M
	Investing Cash Flow
27.35M	21.36M	29.05M	-38.95M	2.33M	-29.86M
	Financing Cash Flow
8.10M	21.23M	-294.00K	-1.64M	125.51M	9.51M

Apollomics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.71
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 6.71 is below the 20-day moving average (MA) of 8.01, below the 50-day MA of 7.72, and below the 200-day MA of 12.31, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 43.82 is Neutral, neither overbought nor oversold. The STOCH value of 9.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.

Apollomics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
REGN	78 Outperform	$67.45B	16.09	15.95%	0.14%	8.27%	10.35%
GILD	75 Outperform	$140.11B	293.83	2.28%	2.76%	6.16%	-91.54%
VRTX	64 Neutral	$124.29B	―	-3.15%	―	11.64%	-114.72%
BNTX	54 Neutral	$22.08B	―	-3.38%	―	-27.64%	-172.62%
Sector *	48 Neutral	$6.86B	1.11	-50.22%	2.47%	16.71%	1.53%
MRNA	48 Neutral	$9.93B	―	-28.77%	―	-52.75%	25.00%
APLM	39 Underperform	$7.40M	―	-149.31%	―	―	―